Diligence memo · auto-generated · as of July 1, 2026

Irisys, Llc

Irisys, Llc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Irisys, Llc operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Irisys, Llc has raised $6.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.3M on 2015-01-29.

Most recent recorded round closed around 2015-01-29.

Valuation (modeled)modeled

Provath models Irisys, Llc at approximately $195M (range $7.2M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.99× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era. Within the normal band (99% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 11.4 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 46% of Pharmaceuticals peers (1610 compared).

Modeled value ranks above 68% of those peers.

Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, OncoQuest Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.